Literature DB >> 10971791

Polymorphisms of the beta2-adrenergic receptor gene (ADRB2) in relation to cardiovascular risk factors in men.

R Rosmond1, O Ukkola, M Chagnon, C Bouchard, P Björntorp.   

Abstract

OBJECTIVE: To investigate the effect of polymorphisms in codon 16 (Arg16Gly) and codon 27 (Gln27Glu) of the beta2-adrenergic receptor gene (ADRB2) on anthropometric, endocrine, metabolic and haemodynamic variables.
DESIGN: A cross-sectional study.
SUBJECTS: A subgroup of 284 Swedish men from a population sample of 1040 at the age of 51 years. MAIN OUTCOME MEASURES: Genotype examination of ADRB2 polymorphisms in codon 16 and codon 27 with polymerase chain reaction and restriction fragment length polymorphism. Anthropometric measurements included body mass index, waist-to-hip ratio and abdominal sagittal diameter. Endocrine measurements included blood levels of testosterone, insulin-like growth factor I, and leptin plus salivary cortisol. Overnight fasting values of serum insulin, blood glucose, triglycerides, total, low and high density lipoprotein cholesterol, as well as blood pressure and resting heart rate, were also determined.
RESULTS: Polymorphisms were frequent in both codon 16 and codon 27. The Arg16Gly genotype showed significant relationships to elevated central distribution of body fat and to systolic blood pressure, whilst the Glu27Glu genotype was associated with elevated leptin and triglyceride levels but not to other measurements, including obesity variables.
CONCLUSIONS: We conclude that only a few cardiovascular risk factors are associated with DNA sequence variation in the ADRB2 in Swedish men.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971791     DOI: 10.1046/j.1365-2796.2000.00721.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol.

Authors:  Orly Vardeny; Gabriel Nicholas; Alina Andrei; Kevin A Buhr; Matt P Hermanson; John J Moran; Michelle A Detry; James H Stein
Journal:  Am J Hypertens       Date:  2012-05-31       Impact factor: 2.689

Review 2.  β-Adrenergic receptor, an essential target in cardiovascular diseases.

Authors:  Daniel Chikere Ali; Muhammad Naveed; Andrew Gordon; Fatima Majeed; Muhammad Saeed; Michael I Ogbuke; Muhammad Atif; Hafiz Muhammad Zubair; Li Changxing
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 3.  Genetics of arterial hypertension and hypotension.

Authors:  Dieter Rosskopf; Markus Schürks; Christian Rimmbach; Rafael Schäfers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-30       Impact factor: 3.000

Review 4.  Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics.

Authors:  Julie A Johnson; Steven G Terra
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

5.  The Glu27 genotypes of the beta2-adrenergic receptor are predictors for severe coronary artery disease.

Authors:  Khaled K Abu-Amero; Olayan M Al-Boudari; Gamal H Mohamed; Nduna Dzimiri
Journal:  BMC Med Genet       Date:  2006-03-30       Impact factor: 2.103

6.  Influence of b2 adrenergic receptor polymorphism (rs1042713 and rs1042714) on anthropometric, hormonal and lipid profiles in polycystic ovarian syndrome.

Authors:  Maha H Daghestani; Maha Omair; Mazin Daghestani; Sonya S Abdel-Razeq; Namik Kaya; Arjumand Warsy
Journal:  J Med Biochem       Date:  2021-01-26       Impact factor: 3.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.